It’s being expected that by 2030, the Wearable Injectors market cap will hit USD 13.9 billion at a CAGR growth of about 11.8%.
Wearable injectors market is increased by occurrence of chronic diseases in large amount across the globe. Growth of the wearable injectors market is supposed to rise in number of diabetes and cancer, and acceptance of developed products.
The global wearable injectors industry is increased by advantages over traditional devices which are controlled in large volume of dose and subcutaneous injection. Wearable injectors offering customization are the need of patient, drug delivery to patients in comfortable manner and comfortable criteria of manufacturing with less risk of regulation. Main advantage of wearable injectors is that it limits the amount of intravenous injections given to patient and allows less frequency of dose with pain which results in improving the patient’s immunity during the treatment.
Developments in technology in wearable injectors like Bluetooth integrated wearable injectors, allows sending the signals to patients, like reminder for injection and offers accessing of data to patients for the therapy. Smart functionality offers connectivity to healthcare network. There are some devices which have buttons and are accessible through clothing and prevent accidental activation which can signal through the visual and audio indicator. Patients can administer drugs intravenously on their own in less time and with less effort by other routes.
Occurrence of lifestyle-based diseases like hypertension and diabetes, is projected to expand over the forecast period. These diseases allow monitoring of several physiological parameters, like blood sugar levels and blood pressure. Thus, combining data of healthcare with wearable injectors, which is further sent to doctors or physicians giving real-time access with less errors, is projected to increase the wearable injectors industry.
Large volume wearable injectors market is an advanced version of self-injecting devices, estimated to grow from a huge base of customer. There are many injectors available for insulin delivery. From Insulet Corporation, OmniPod, is well-known device that generated a significant growth of revenue. For the administration of non-insulin biologic, one large volume wearable injector is approved. In spite of doubts regarding approval and device development, several companies are contributing their money, resources and time to develop these devices. Many of the pharma companies have many secret programs which can provide necessary growth to the wearable injectors market over the forecast period.
The global wearable injectors industry is segmented on the basis of applications, type, end-user and region. On the basis of application, wearable injectors market is divided into diabetes, infectious diseases, oncology, cardiovascular diseases and autoimmune disorders. Segment of oncology controlled the global wearable injectors market and is continued over the forecast period. On the basis of type, wearable injectors industry is divided into off-body wearable injectors and on-body wearable injectors. On-body wearable injectors segment holds the maximum share in the global wearable injectors industry in terms of revenue. Based on end-user, wearable injectors market is divided into clinics, hospitals, home-care settings and many more.
On the basis of geography, regions involved in increasing the global wearable injectors market share are Europe, Latin America, North America, Asia Pacific and Middle East & Africa. North America holds the maximum share of wearable injectors market and is anticipated to grow in the coming years. Asia Pacific is the fastest growing region and is estimated to increase over the forecast period.
Key company profile in the Global Wearable Injectors Market Are Amgen, Becton, Dickinson and Company, Dexcom, Inc., Enable Injections, Insulet Corporation, Sensile Medical, Tandem Diabetes Care, Inc., Ypsomed, F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd.
Wearable Injectors Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2030||USD 13.9 billion|
|Growth Rate||CAGR of 11.8% during 2021-2030|
|Segment Covered||Component, Application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||Amgen, Becton, Dickinson and Company, Dexcom, Inc., Enable Injections, Insulet Corporation, Sensile Medical, Tandem Diabetes Care, Inc., Ypsomed, F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd.|
Key segments of the Wearable Injectors Market
by Technology, (USD Billion)
- Rotary Pump
- Expanding Battery
By Therapy, (USD Billion)
- Cardiovascular disease
- Other disease
By Application,(USD Billion)
- Infectious diseases
- Cardiovascular Diseases
- Autoimmune Disorders
By Type, (USD Billion)
- Off-body Wearable Injectors
- On-body Wearable Injectors
Region Overview, (USD Billion)
- North America
- United States of America
- the Netherlands
- The United Kingdom
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South America
- Rest of South America